Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus. 1991

M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
Medical Department C, Bispebjerg Hospital, Copenhagen Denmark.

The effect of a sustained-release verapamil preparation on glucose metabolism was investigated in 10 patients with non-insulin dependent diabetes mellitus. In a single blind cross-over study verapamil 240 mg b.d. for 1 week lowered fasting plasma glucose from a mean value of 11.6 mmol/l to 10.3 mmol.l-1, and the fasting glucose appearance rate was decreased from 1.5 to 1.2 mmol.min-1. The decrease in fasting plasma glucose and glucose appearance rate was not related to the steady state plasma concentration of verapamil, nor-verapamil and the metabolites D.617 and D.620. After oral glucose administration a tendency to lower plasma glucose values was found after verapamil administration. Plasma insulin, C-peptide, total and C-terminal glucagon were not significantly different in the placebo and the verapamil studies, neither in the fasting state nor after glucose. It is concluded that brief verapamil treatment decreases fasting plasma glucose and glucose turn-over in non-insulin dependent diabetics, possibly by inhibition of gluconeogenesis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
January 1982, Acta medica Scandinavica,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
August 1998, Metabolism: clinical and experimental,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
January 1981, Acta medica Scandinavica,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
January 1995, Clinical therapeutics,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
October 1988, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
January 1991, Problemy endokrinologii,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
April 1995, The American journal of clinical nutrition,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
October 1994, Israel journal of medical sciences,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
January 1995, The Journal of international medical research,
M Busch Sørensen, and H Sjøstrand, and H Sengeløv, and M Tiefenthal Thrane, and J Juul Holst, and J Lyngsøe
October 1992, Acta endocrinologica,
Copied contents to your clipboard!